Purpose: To evaluate the efficacy of prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH) for prostates 80 g. Materials: Patient demographics, International Prostate Symptom Score (IPSS), Quality of Life score (QOL), prostate volume assessed by MRI, maximum urinary flow (Qmax), and post-void residual (PVR) volume were evaluated as part of an IRB-approved retrospective analysis at a single institution. Exclusion criteria included patients with active urinary tract infection, renal failure, or severe atherosclerosis. Results: Between January 2014 and September 2017, 110 patients underwent PAE for BPH with prostate size 80 g. Mean patient age was 69.0 years, mean baseline QOL was 4.7, and mean prostate volume was 153.7 g. At 1, 3, 6, and 12 months, QOL score improved to 1.6, 1.0, 0.9, and 1.1, respectively (p<0.001 for all). At 3 and 12 months of follow-up, mean prostate volume had decreased to 105.4g (p<0.001) and 96.1g (p<0.001). Among the 85 (77.3%) patients non-reliant on bladder catheterization prior to